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Abstract

A highly cross-linked polystyrene resin bearing a reactive chlorostannane moiety 1 has
been used to generate a variety of arylstannane radiopharmaceutical precursors for no-carrieradded radioiodination. The resins were characterized for their solvent compatibility and
sensitivity to acid cleavage. Resin-supported arylstannanes synthesized via their aryllithium
analogues include 3- and 4-stannylbenzaldehydes, 3- and 4-stannylbenzoic acids, and 3- and 4N-succinimidyl benzoates. A three-step route to the resin-supported stannylbenzoic acids 12a/b
was developed through resin-supported benzaldehydes 11a/b. The aldehyde to acid conversion
efficiency is >90%, and acid loading capacities of 0.66−0.94 mmol/g were obtained. Resinsupported N-succinimidyl benzoates 16a/b were prepared from the acid with 78−84% conversion
efficiency. Libraries of resin-supported benzamides 19a/b prepared from amine conjugation to
corresponding benzoic acids or N-succinimidyl benzoates are described. A third approach
describes the preparation of resin-supported benzamides via direct conjugation of the dilithio salt
of the intact benzamide to the chlorostannane resin 1. Lastly, as proof-of-principle, a
radiolabeling study with iodine-131 (131I) was performed with a resin-supported benzamide to
afford the corresponding radioligand in moderate yields, and high radiochemical purity.

Key Words: Solid phase organic chemistry (SPOC), radiopharmaceuticals, iodobenzamides, Nsuccinimidyl benzoate, radioiodination.
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Introduction

We have been investigating the applicability of insoluble resin-supported arylstannanes
as precursors to radioiodinated pharmaceuticals with potential for diagnosis and therapy.1-6 The
selected polystyrene (PS) resin-supported tin compound is not commercially available but its
preparation had been previously reported along with numerous applications.7 This resin has been
further adapted for the preparation of radioiodinated pharmaceuticals by preparing a resinsupported chlorostannane 1 (Fig. 1) as the precursor to arylstannanes of specific biological
activity. As illustrated in Figure 1, the resin of interest is a copolymer of divinylbenzenes and 3{dibutyl[2-(3-and 4-vinylphenyl)ethyl]stannyl chloride}, itself prepared from the
divinylbenzenes by mono-hydrochlorostannylation with dibutylchlorostannane.8
[FIGURE 1]
Two routes to resin-supported arylstannane precursors were envisioned, each involving
aryllithium reagents (Fig. 2); one being the direct attachment of aryl-containing ligands of
interest (Route A) and the second involving intermediate arylstannanes (Route B). Both
approaches are reported here. One advantage of solid phase organic chemistry is the ability to
drive reactions to completion by using excess reagents. Analogously, the resin-supported
precursor is present in excess (mg) during radiolabeling since the radioisotope is typically the
limiting (ng) reagent. Hence, advantageously, the consumption of the typically expensive
radioisotope can be driven to completion (Fig. 2). A further advantage of resin-based precursor
radiolabeling is the rapidity in separating resin-bound tin materials, either the tin precursor or
insoluble reaction by-product(s), by simple filtration of the resin to afford chemically pure
radiolabeled compound in solution.
Tin-aryl bonds are susceptible to cleavage by many electrophilic reagents, including
acids, halogens, B2H6/H2O2, and NOCl.9-10 While this places limitations on the chemistry that
can be performed on the resin-supported arylstannanes without loss of the aryl group, it also
creates advantages at the time of detachment. Beyond the use of electrophilic radioiodine, acids
represent an interesting case where replacement of tin by hydrogen, results in a traceless linker.11
[FIGURE 2]
Both direct and indirect approaches to preparing resin-bound radiopharmaceutical
precursors, typically through a PS system, have been described previously by our group and
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others. Direct attachment of the appropriate aryl lithium intermediate to resin 1 afforded the
resin-bound precursor for [131I]-N-isopropyl-4-iodoamphetamine ([131I]-IMP), a SPECT imaging
agent for monitoring brain perfusion.1 Treatment of this resin with radioiodine produced [131I]IMP in 44% radiochemical yield (RCY). Meta-iodobenzylguanidine (MIBG) is another
compound that can be produced by a resin-bound precursor method. A four-step indirect
approach was used to make the resin-supported 3-stannylbenzylguanidinium, beginning with
lithiation of protected 3-bromobenzylamine and coupling with resin 1.2-5 Radiolabeling with this
resin has been scaled-up to the curie level as the route to no-carrier-added Azedra ([131I]MIBG),12 and is currently in multi-center phase 2b clinical trials as a radiotherapeutic for
malignant pheochromocytoma, a rare adrenal tumor, and pediatric neuroblastoma, the most
prevalent cancer in children.13-14 This specific resin has been further exploited as a convenient
precursor to [211At]-meta-astatobenzylguanidine ([211At]-MABG),15 used in alpha-particle
emitting therapy of micrometastatic neuroendocrine tumors. A multi-step resin approach has also
been applied to the 123I-radioiodination of Congo Red in >56% RCY and >99% radiochemical
purity (RCP), as an azo dye that localizes to forms of β-amyloid.16
PS resin-bound alkenyl stannyl precursors comprised of an alkenyl-tin bond have also
been used for preparing a broad range of biologically active radiopharmaceuticals by
radioiododestannylation.17-20 Examples of 125I-labeled vinyl iodides prepared by the resin-route
include (E)-1-[125I]-iododecene used en route to synthetic fatty acids and the acetate-protected
analogue of (E)-17α-[125I]iodovinylestradiol for targeting the estrogen receptor.21 These
compounds were obtained in 20-70% RCY.21 Recently, a resin-bound stannylpropenyl mesylate
was reported as a prosthetic group for attachment to diverse amines, and can be extended to
alcohols, thiols, and peptide-based drug structures.22
A solid-phase strategy to macromolecular radiopharmaceuticals has also been described
using a hydrophilic PEG-based resin.23 In particular, the preparation of the small molecule
bioconjugate N-succinimidyl-3-[125I]iodobenzoate ([125I]SIB) from a PEG resin-supported
precursor was used to radiolabel a tomato plant systemin peptide and two proteins, globular
albumin and IgG antibody. Analogous methods to radiopharmaceutical preparation include the
use of soluble fluorine-rich supports that combines the advantage of purification and
characterization of fluorous-tagged intermediate compounds. Most of the work to date has used
fluorous arylstannanes as precursors to radioactive aryl iodides.24-26 A hybrid fluorous solid-
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phase radioiodination platform has similarly been used to provide “carrier-free” solutions of
radiolabeled agents, including [125I]-MIBG.27 In recent years, a PS-resin based
organotrifluoroborates has been synthesized towards preparing radioiodinated ligands.28-30
Described herein is the synthesis, physical, and chemical characteristics of resinsupported arylstannanes as precursors for radiolabeling with radioiodine. In particular, we
describe resin-supported benzaldehydes, benzoic acids, N-succinimidyl benzoates, and
benzamides. Benzaldehydes, benzoic acids, and N-succinimidyl esters are versatile functional
moieties that can be used as radiolabeled bioconjugates, particularly for amine-bearing
radiopharmaceuticals, such as amino acids, peptides, and proteins. Benzaldehyde resins also
participate in condensation reactions with Schiff bases and aldols for the library synthesis of
functionalized heterocycles via α,β-unsaturated ketones.31
Halogenated benzamides themselves are of interest as nuclear imaging agents.32-33 In
particular, structural analogues of N,N-dialkylamino-alkyl iodobenzamides with positional
isomers of the halide, with different mono- and di-substituted N-alkyl groups, and varying
number of methylene bridge groups, have ranges of selectivity towards biological targets that are
considered imaging biomarkers in cancer.34-40 Resin-supported 3- and 4-arylstannyl
intermediates provide an opportunity to produce diverse libraries of radioiodobenzamide
precursors to systematically assess structure activity relationships of various biological targets.

Results and Discussion

Synthesis and characterization of resins
Composition
Resin 1 used in this study was a copolymer prepared from commercial 20 mol-% 3- and
4-divinylbenzenes (DVB) and 80 mol-% 3-{dibutyl[2-(3-and 4-vinylphenyl)ethyl]stannyl
chloride}, with the latter prepared by mono-hydrochlorostannylation of DVB with
dibutylchlorostananne.8 The resin produced from emulsion polymerization and rapid stirring was
an insoluble powder 10−300 µm in diameter, with a porous surface as revealed by scanning
electron microscopy (SEM, see supplemental data, Fig. S1). This material was chemically
characterized by a combination of solid phase magic angle spinning (MAS) 119Sn NMR and
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diffuse reflectance infrared Fourier transform (DRIFT) IR spectroscopies, and by quantification
of chemically released tin-bound species by hydrolysis or iodinolysis reactions.
Treatment of resin 1 with ethanolic NaOH at room temperature (RT) released free
chloride ions, which upon titration revealed a Sn−Cl resin loading capacity of 1.7 mmol/g, as
shown in Figure 3. The 119Sn NMR spectra before hydrolysis showed a single peak at 140−150
ppm, reflective of a stannyl chloride group. This peak was replaced by two overlapping peaks at
91 and 101 ppm after hydrolysis attributed to a combination of stannol 2 and stannoxane 3.8
Refluxing the hydrolyzed resin in 6 mol/L HCl regenerated resin 1, as confirmed by 119Sn NMR.
[FIGURE 3]
The amount of chloride released was used to calculate the proportions of the two
monomers incorporated into the resin, assuming all chloride released on hydrolysis came from
the chlorostannane monomer. A loading capacity of 1.7 mmol chloride/g of resin 1 translated
into a resin comprised about 60% DVB and 40% 3-{dibutyl[2-(3-and 4vinylphenyl)ethyl]stannyl chloride. This stood in stark contrast to the 20:80 proportion of
monomers used to prepare the co-polymer. We do not have a satisfactory interpretation of this
change.

Solvent compatibility
Resin 1 was prepared with a very high degree of crosslinking agent (20%), compared
with a 1−2% cross-linking agent used to produce most commercially available PS resins. Despite
high cross-linking, resin 1 could repeatedly rapidly incorporate and dispel a variety of solvents.
Solvent incorporation was monitored both by observing the increase in the apparent volume of
the resin when wetted and by following the increase in weight and its subsequent decrease upon
air filtering. Table 1 shows the ratio of the weight of solvent incorporated to the weight of resin
and the volume ratio. Both ratios were a factor of 1−3 in several solvents, with the weight ratio
being somewhat larger. The incorporation occurred almost immediately upon wetting. The
volume ratio was determined visually, while the weight ratio was measured by following the
decrease in weight when the wetted resin was exposed to the atmosphere. Except for DMSO, the
solvent was rapidly lost depending on its volatility (≤ 30 min) and the resin returned to its
original weight. Resin 1 would not wet with water alone.
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Resin 1 was converted to a 3-stannyl benzylammonium resin 4 (Fig. 4) en route to the
MIBG resin, as described elsewhere.2 The presence of the ammonium groups made the resin
more water compatible, as evidenced by the increase in the weight ratio relative to resin 1 (Table
1, second column), allowing for the investigation of aqueous-based reactions. Concurrently, resin
4 was less hydrocarbon compatible, as the last two columns of Table 1 indicate.
[TABLE 1]

Protodestannylation
Resin 4 was used to monitor the stability of the tin-aryl carbon bonds under acidic
conditions in order to determine which acid catalyzed transformations can be carried out without
concomitant loss of aryl groups. The initial loading capacity for resin 4 was determined by I2mediated iodinolysis, releasing 3-iodobenzylammonium 5 (Fig. 4). The filtrate following resin
separation was subsequently analyzed by HPLC for quantification of 5 and indicated a loading of
1.30 mmol/g of resin. The progress of the protodestannylation reaction was similarly followed by
HPLC to measure the amount of benzylammonium 6 released.
[FIGURE 4]
Various protodestannylation conditions were chosen to determine effects on the reaction
rate. Treatment of resin 4 with 0.4 mol/L HCl in EtOH/H2O at RT revealed slow release of 6
(Supplementary data, Fig. S2). Yields plateaued at 0.55 mmol/g, which is only 43% of the
maximum loading of resin 4. Similar results were obtained using other strong acids (e.g., TFA
and H2SO4) in a mixture of aqueous and non-aqueous solvents suggesting that the rate of
protodestannylation is not dependent on the anion present. Weaker acids, like HF and AcOH,
were unable to release 6 under these conditions. In contrast, 1% TFA in dichloromethane (DCM)
(0.4 mol/L) released 1.26 mmol/g of 6 within 15 min at RT. Refluxing resin 4 for 11.5 h in 0.4
mol/L HCl in EtOH/H2O, afforded a similar result, releasing 1.21 mmol/g of 6.
These results established the parameters for using mild acid catalysis with the resin, since
1 h HCl treatment released ≤5% of the maximum loading of resin 4 (i.e. 0.05 mmol/g of 6). On
the other hand, protodestannylation can be driven to completion by refluxing in HCl/EtOH/H2O
or almost immediately with TFA/DCM at RT in non-ionizing solvent. The plateau in the slow
release of 6 under mild EtOH/H2O conditions suggests that about 40% of the benzylammonium
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groups are more readily available for reaction than the remaining tin-aryl groups. However, all
benzylammonium groups will react under more forcing conditions.

Synthesis and characterization of resin-supported radiopharmaceutical precursors

Resin-supported 3- and 4-stannyl benzoic acids 12a and 12b (direct versus indirect approach)
Arylzinc benzoate derivatives have been used for coupling to Sn−Cl containing fluorous
soluble supports and have an advantage given the wide functional group tolerance of arylzinc
species in cross-coupling reactions.24, 26 Similarly, the solution-phase analogue of resin 1,
tributylchlorostannane, reacts with the dilithio salt of bromobenzoic acids for arylstannylation.41
Interestingly, the analogous approach using resin 1 as a direct route to resin-supported benzoic
acids through lithiated salts of 3- or 4-bromobenzoic acid proved unsuccessful.
We decided to explore the versatility of the organolithium approach using protecting
groups. Given the acid sensitivity of the tin-aryl bond, the choice of protecting groups was
somewhat limited, thus an indirect approach for obtaining resin-bound benzoic acids was
deemed necessary. Oxazolidine-protected benzaldehydes were chosen as an appropriate
intermediate, whereby the aldehyde was first masked with pseudoephedrine and later removed
with dilute AcOH.42-43 Resin-supported 3- and 4-stannyl benzoic acids 12a and 12b were
obtained by this indirect route (Fig. 5, where “a” consistently labels the 3-substituted arylstannyl
resins and “b” the 4-substituted arylstannyl derivatives).
[FIGURE 5]

(i) Resin-supported 3- and 4-stannyl oxazolidinylbenzenes, 10a and 10b
Refluxing 3- or 4-bromobenzaldehyde (7a/b) with pseudoephedrine (8) in benzene
produced the corresponding bromo-oxazolidines (9a/b) in near quantitative yield (Fig. 6).
Oxazolidine derivatives 9a/b were then treated with n-BuLi to produce the aryl-lithium
intermediate in situ. To these solutions was added resin 1 as the limiting reagent (0.5 equiv.) to
ensure complete conversion of Sn−Cl to Sn−aryl.
Analysis of the resultant resins by solid phase MAS 119Sn NMR showed one signal at 41.8 and -42.1 ppm for resins 10a and 10b, respectively (for examples of representative spectra
see Supplemental data). The absence of a peak in the range 140−150 ppm indicated that all
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Sn−Cl sites on the resin had reacted and were occupied by aryl groups. To obtain the solid phase
MAS 119Sn NMR spectra, resins were swollen in either CHCl3 or toluene. This had the effect of
narrowing the resonance peaks, allowing two peaks within 3−4 pm to be clearly identified. In
addition to the normal C−H and aromatic absorptions from the resin’s backbone, solid phase IR
spectra of these resins showed the presence of a C−O stretch at 1044 and 1048 cm-1 for resins
10a and 10b, respectively, consistent with the presence of the oxazolidine.
Iodinolysis proved to be an unreliable method of analysis for resin-supported 10a and
10b. The oxazolidine ring was unstable under iodinolysis conditions with the parent oxazolidine
accounting for <10% of the total area under the curve in HPLC. Consequently, loadings of resins
10a/b were not determined.

(ii) Resin-supported 3- and 4-stannyl benzaldehydes, 11a and 11b
Resins 10a/b, treated with a mixture of AcOH, MeOH and H2O (5:5:1) at RT for 24 h,
afforded resin-bound benzaldehydes 11a/b and were subsequently analysed by the three methods
mentioned above. The 119Sn NMR spectrum of the 4-stannylbenzaldehyde resin 11b showed one
signal at -39.8 ppm. This change in chemical shift from -42.1 to -39.8 ppm, although small, was
seen consistently. The IR spectrum showed characteristic aldehyde absorptions in addition to the
usual polymer backbone signals. Additionally, the C−O absorption stretch of the oxazolidine at
1048 cm-1 had disappeared. The IR spectrum confirmed the oxazolidine to aldehyde conversion
but could not be used to quantify the extent of conversion. Iodinolysis and subsequent HPLC
analysis of 4-iodobenzaldehyde 13b released indicated a loading capacity of 0.78 mmol/g for
resin 11b. Similarly, HPLC analysis of resin 11a showed 1.05 mmol of 3-iodobenzaldehyde 13a
per gram of resin. 119Sn NMR and IR spectra showed results similar to that of resin 11b.
Given that the oxazolidine hydrolysis conditions could promote protonolysis, the stability
of the tin-aryl bond was confirmed by treating resin 11b for an additional 25 h at RT. HPLC
analysis post iodinolysis indicated that resin 11b loading remained steady at 0.78 mmol/g.

(iii) Resin-supported 3- and 4-stannyl benzoic acids, 12a and 12b
The susceptibility of the Sn−aryl bond to acid protonolysis limited the choice of
oxidizing agents for the conversion of the aldehyde to the acid. Hence, the focus was on agents
such as the peroxyacids (i.e., peracetic acid, 3-chloroperbenzoic acid (mCPBA)) and the
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peroxides (i.e., benzoyl peroxide and oxone). With resin 11b, peroxides gave incomplete
conversion to acid, as evidenced by iodinolysis product mixtures of 13b and 4-iodobenzoic acid
14b. Interestingly, the 119Sn NMR chemical shifts seemed somewhat sensitive to the substituents
on the aromatic ring. In the case of the 3-substituents on resin 11a, the carbaldehyde and
carboxyl groups showed 119Sn chemical shifts at -39.2 and -41.3 ppm, respectively. In cases
where there were similar amounts of the aldehyde and acid, two overlapping closely spaced
peaks could be observed (Supplementary data, Fig. S7). This difference in shifts was not
apparent for the 4-substituted resins.
The most efficient conversions with resin 11a were achieved with five-fold excess of
unpurified mCPBA, resulting in a mixture of ~98% acid 14a and ~2% aldehyde 13a following
iodinolysis and HPLC. Similar results were observed with resin 11b: 92−95% acid 14b and
8−5% aldehyde 13b. Unpurified mCPBA contained approximately 7% 3-chlorobenzoic acid, and
use of purified mCPBA reduced conversion to about 50%. Loadings for resin 11a were 0.93
mmol/g acid and 0.01 mmol/g aldehyde, and resin 11b were 0.69 mmol/g acid and 0.03 mmol/g
aldehyde. IR spectra for the acids were consistent with conversion from an aldehyde as seen by
the loss of the dual carbonyl absorptions (1700 and 1646 cm-1), and the appearance of two new
carbonyl signals at 1718 and 1689 cm-1. The former is attributed to a hydrogen-bonded acid
dimer implying that the carboxylic acid groups can be in close contact with each other.

Resin-supported 3- and 4-stannyl benzamides (indirect approach)
A number of coupling reactions were carried out with resin-bound acids 12a/b in an
effort to conjugate amines for the preparation of resin-supported benzamides 15a/b. As shown in
Figure 6, this was examined by (i) amine-conjugation directly to the acid using a coupling
reagent (e.g., DCC) and (ii) formation of an active ester (i.e., N-succinimidyl ester resins 16a/b)
for subsequent amine-conjugation. Radio-iodinolysis of resin 16a releases 17a, which provides a
prosthetic group that has found use in the radiolabeling of diverse amines. While both routes are
sources of radioiodobenzamides (18a/b), the latter method is applicable to amines, amino acids,
and proteins. The former method is restricted to protected amines.
[FIGURE 6]

(i) Direct diamine coupling with resin-supported acids 12a/b
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As illustrated in Figure 7, this study focused on dialkylamino(ethyl or propyl)amines
using either direct coupling or through the resin supported N-succinimidyl esters, 16a/b. Thus,
treatment of 12b, which had a loading capacity of 0.66 mmol of 4-benzoic acid per gram of
resin, with DCC and N,N-diethylethylenediamine gave a benzamide-bound resin (19b-2, Table
2). The 119Sn NMR spectrum showed one peak slightly shifted upfield from the acid. This was as
expected since the structural changes are remote from the tin. The IR spectra were consistent
with a benzamide structure. Iodinolysis and HPLC confirmed 0.40 mmol of 2-(N,Ndiethylamino)ethyl-4-iodobenzamide and 0.10 mmol of 14b being released per gram of resin.
The presence of 14b indicated that amide formation had not gone to completion under these
conditions, the acid to amide conversion was 60%.
[FIGURE 7]
A small library of resin-bound dialkylaminoethyl benzamides 19b from resin 12b was
produced using the DCC amine-coupling method by substituting different diamines (Table 2).
The 119Sn NMR spectra of the resin-bound benzamides were all similar, showing one signal
between -39.8 and -41.2 ppm. IR spectra showed the appearance of amide carbonyl absorptions
between 1637 and 1658 cm-1. The iodobenzamides released from the small library of resins 19b
are putative ligands for σ-receptors based on structure−activity relationships,44 including N-(2diethylaminoethyl)-4-[123I]iodobenzamide ([123I]I-BZA) from resin 19b-2, which has favourable
σ-receptor binding and has been successfully used clinically to image malignant melanoma.34-35
Interestingly, binding affinity studies show that 5 of the iodobenzamides have affinities
improved over I-BZA (data not shown). Additional studies are needed to determine if this
enhancement in affinity extends to improved radiopharmaceutical behaviour in vivo.
[TABLE 2]

(ii) Coupling using resin-supported N-succinimidyl ester intermediates 16a/b
N-succinimidyl-radioiodobenzoates are well-established prosthetic groups for the
labeling of amines, amino acids, and peptides.41, 45-46 Traditionally, they are produced from the
corresponding N-succinimidyl tributylstannylbenzoates,41 and this solution phase approach
necessitates cumbersome HPLC purification to remove toxic organotin compounds from the
labeled product. Resin-supported stannyl N-succinimidyl esters (16a/b) circumvent these
challenges. As shown in Figure 6, resins 16a/b can serve as a bioconjugate by two approaches,
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with the first being through amine coupling to resin-supported benzamides, or by first releasing
the prosthetic group into solution and then conjugating to the amine-containing ligand of choice.
Herein we demonstrate the former approach.
Resins 16a/b were obtained by treating resins 12a/b with EDC and Nhydroxysuccinimide (NHS). The 119Sn NMR spectra showed one signal for resins 16a/b that
wase only slightly shifted from that of the acid. IR spectra showed the presence of appropriate
carbonyl absorptions from the NHS moiety. Iodinolysis and HPLC analysis of resins 16a and
16b revealed the presence of 0.69 mmol/g and 0.53 mmol/g of N-succinimidyl 3- and 4iodobenzoate, respectively.
Resin 16a was treated with three N,N-alkylpropylenediamines at RT for 24 h to obtain
resin-supported benzamides 19a-1 through 19a-3, whereas resin 16b was similarly treated with
N,N-diethylethylenediamine to afford resin 19b-2. These specific resins were prepared, since the
corresponding iodobenzamides had the more promising binding affinities to σ-receptors (data not
shown). As presented in Table 3, this small library of resin-supported benzamides were prepared
with >96% efficiency from resins 16a/b and had variable benzamide loadings ranging from
0.43−0.75 mmol/g. These results show that the NHS ester intermediates are similarly efficient at
producing resin-bound stannyl benzamides 19a/b as through amine-DCC coupling to the acidbound resins 12a/b. Regardless of the route, final resin-bound benzamide preparations contained
20−40% benzoic acid moieties.
[TABLE 3]
In comparison to the good conversions experienced in obtaining the resin-supported acids
from the aldehydes, the lower conversions to the amides encouraged us to look in more detail at
this process. When resin 12b was treated with an alternative coupling agent DIC with 1-HOBT
in DCM without subsequent addition of amine, the resultant resin showed two carbonyl
absorptions at 1705 and 1784 cm-1, consistent with the symmetric and asymmetric stretches for
an anhydride. This suggested that rather than remaining as active esters, a significant number
reacted with adjacent carboxylic acid groups to form anhydrides. The IR spectrum of the acid
itself had revealed a carbonyl band at 1718 cm-1, consistent with hydrogen bonded acid dimers in
support of this conjecture.
Subsequent reaction of the resin-supported anhydride with amine would result in
equimolar amounts of amide and recovered acid. In an attempt to bypass this problem, several
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reaction parameters were tested without any improvement in conversion efficiency of acid to
amide: reaction time was varied from several hours to days, coupling reagents were changed, and
the sequence of reagent addition was modified, and the resin was re-treated.
The apparent inevitability of obtaining amides contaminated with significant amounts of
acid and relatively enhanced amounts of aldehyde suggests that this route is of limited interest
for the production of individual radiolabeled benzamides. However, a fast and convenient
purification process was developed using solid phase extraction (SPE) of post-release mixtures
of compounds from resins 19a/b. Following this method, iodobenzamides were isolated in 10
min with chemical purity >90% (see Supplementary data for further description).
A comparison of the resin approach and the traditional approach seems appropriate given
the need for a separation step with the resin. The resin approach involves separating an acid, a
base, and a neutral, which was accomplished using SPE. The traditional approach through a trin-butylstannylated benzamide involves the separation of the reputedly toxic tin tri-n-butylated
precursor from the desired radioiodinated benzamide. The precursor is used in large excess and
both the precursor and product are lipophilic and typically provide a difficult separation and rely
upon a final HPLC purification step.

Resin-supported 3- and 4-stannyl benzamides (direct approach)
Resin-supported 3- and 4-stannylbenzamides 19a/b, prepared from either resins 12a/b or
16a/b, allowed production of small libraries of iodobenzamides. However, with incomplete
conversions over the multistep synthesis, significant contaminants were observed. While an
albeit fairly rapid and simple purification procedure was established to remove the iodobenzoic
acid and iodobenzaldehyde contaminants, this would not be feasible in scaling up the
commercial production of radiohalogenated benzamides. Consequently, a direct route from the
conjugation of chlorostannane resin 1 with lithio derivatives of bromobenzamides was explored
as a convergent approach to resin-supported benzamides 19a/b.
A concern arises about the two competitive pathways for the reaction of
bromobenzamides with an organolithium reagent: bromine-lithium exchange (transmetallation)
and deprotonation.47-50 Addition of a concentrated solution of the alkyllithium reagent (i.e., ~2.5
mol/L n-BuLi) to bromobenzamide led to internal quenching of any aryllithiated intermediates,
most likely due to n-BuLi being in aggregate form.48 This quenching phenomenon can be
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minimized and altogether avoided by using a dilute solution of the organolithium to guarantee it
being in monomeric form, and by inverting the mode of addition.47-49
A modified procedure was consequently devised and optimized where bromobenzamide
solution was “inversely” added to a dilute THF solution of 3 equiv. of monomeric alkyllithium
(i.e., 0.03 mol/L t-BuLi) with rapid stirring at -78°C (Fig. 8). Quenching studies with MeOD
confirmed the formation of the dilithio salt of the bromobenzamide. Subsequently, 0.5 equiv. of
resin 1 were added in slow portions. Four 4-bromobenzamides were treated in this manner, and
the preparation of the resin-bound 4-stannyl benzamides was verified via iodinolysis followed by
HPLC, 119Sn NMR, and IR spectroscopies.
[FIGURE 8]
Iodinolysis revealed benzamide loadings for respective resins as follows: 19b-9, 0.37
mmol/g; 19b-10, 0.25 mmol/g; 19b-11, 0.17 mmol/g; and 19b-12, 0.53 mmol/g. In each case, the
4-iodobenzamide was the only product observed by HPLC. 119Sn NMR spectra showed a major
signal around -41 ppm, attributable to the Sn−aryl bond, and a smaller broader peak around -82
ppm, assigned to Sn−O. The IR spectra were consistent with the assigned benzamide structure.
The direct approach from conjugation of resin 1 to lithiated N-alkylbromobenzamides
gave yields comparable to the indirect approach through resins 12a/b, but the former has the
advantage of producing material in high chemical purity. This would be of considerable value for
production of radiopharmaceuticals with established biological potential, since additional
purification steps require time, and result in concomitant loss of radioactivity.
Radiolabeling with 131I
Because carbamide groups are deactivators in electrophilic aromatic substitution
reactions such as radioiodination, resin-supported benzamide 19b-7 was chosen to illustrate
radiolabeling with 131I (half-life (t1/2) = 8 d) as proof-in-principle. No attempt was made to
optimize the labeling yields of the resin-supported precursor 19b-7 to N-(2-morpholinylethyl)-4iodobenzamide (20b-7). The reaction mixture from the radioiodination of 19b-7 was also chosen
to test the radioiodobenzamide purification process. Radiolabeling with ~150 MBq (4.05 mCi) of
[131I]NaI with peracetic acid as oxidant resulted in a mixture of radiolabeled compounds: [131I]N-(2-morpholinylethyl)-4-iodobenzamide (~50% RCY); [131I]-4-iodobenzaldehyde (~10%
RCY); [131I]-4-iodobenzoic acid (~20% RCY), as estimated by radioHPLC (Fig. 9). Following
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SPE purification, radioiodobenzamide was obtained with >90% RCP and 37% RCY. [131I]-4iodobenzaldehyde remained around 10%. With good isolated radiochemical purities and
moderate radiochemical yields for initial radiolabeled studies, this encouraging result suggests
room for optimization in using resin-supported arylstannanes towards radiolabeled precursors.
[FIGURE 9]

Conclusions
With an eye to providing effective precursors to iodine labeled radiopharmaceuticals,
resin-supported arylstannanes have been synthesized to provide no-carrier-added radioiodide
compounds free of toxic tin-bearing precursors and side-products that can be difficult to remove.
Resins 1 and 4 were tested for their solvent compatibility and resin 4 for its acid sensitivity.
Described are two library-based approaches and a final direct approach to creating single resinsupported pharmaceuticals of chemical high purity. Resin supported 3-and 4-stannyl
benzaldehydes (11a/b), benzoic acids (12a/b) and N-succinimidyl benzoates (16a/b) were
prepared using aryllithium intermediates. In turn, these were converted to small libraries of
benzamide precursors (19a/b). The conversion of benzaldehydes to benzoic acids proceeded in
high yield and provided iodobenzoic acids with good purity. The conversion of benzoic acids to
benzamides was less successful and was interpreted to proceed to a significant extent through
resin supported benzoic acid anhydrides. A third, more successful approach, involved the direct
conjugation of the dilithio salt of an intact halobenzamide to the chlorostannane resin 1. This
provided iodobenzamides in high purity. Resin 19b-7 was successfully radiolabeled with 131I.
While radiolabeling yields were not optimized in this study, this points the way to using the
approaches developed for solid phase organic chemistry for generating new
radiopharmaceuticals by preparing and screening much larger libraries.
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Experimental

Instruments and materials
Chemicals and reagents were purchased from Sigma-Aldrich, Lancaster or Gelest and
used without further purification unless otherwise indicated. THF and DCM solvents were
freshly distilled from potassium-benzophenone and calcium hydride stills, respectively. SiO2
chromatography was used to remove stabilizers from commercial grade divinylbenzene (DVB)
(with ~20% ethylvinylbenzene).
1

H NMR and 13C NMR spectra were obtained using either a Varian Gemini 300 (300

MHz for 1H) or a Varian Mercury 400 (400 MHz for 1H) spectrometer. 1H NMR spectra of 4disubstituted aromatics were analyzed as AB spectra. Solid phase MAS 119Sn NMR spectra were
obtained on a Varian Infinity Plus 400 spectrometer (400 MHz for 1H) using a Chemmagnetics
7.5 mm probe spinning at an angle of 54.74°. Spectra were obtained with acquisition at 120
MHz, using a 45° pulse with a 5 s delay between pulses. Resins were pre-treated with toluene or
chloroform prior to obtaining 119Sn NMR spectra. A Bruker FT-IR with a Spectra-Tech diffuse
reflectance attachment (DRIFT) was used for resin samples. The Kubelka-Munk conversion was
used instead of an absorbance scale for the resin samples for improved signal to noise ratio. A
Finnigan MAT 8230 Mass Spectrometer was used to obtain the mass spectra.

Proto and iododestannylation procedures for resin 4
Using 1% TFA in DCM
To a 5 mL vial was added resin 4 (50.3 mg, 65.4 µmol), DCM (1.98 mL) and TFA (20
µL, 0.26 mmol). After shaking in a sealed vial for 15 min at RT, the mixture was transferred into
a 25 mL flask and the solvent was removed in vacuo. EtOH (3 mL) and a 0.2 mol/L I2 solution in
EtOH (40 µL, 8 µmol) were added to the residue. After stirring for 3h at RT, a 0.1 mol/L sodium
metabisulfite solution (0.2 mL, 20 µmol) was added. This solution was adjusted to pH=5−6 with
0.1 mol/L NaOH and diluted to 25 mL with H2O. An aliquot was filtered through a syringe filter
and then analysed by HPLC to determine the amount of 5 and 6 released.
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Using 0.4 mol/L HCl in EtOH/H2O, 1:1.25
About 50 mg of resin 4 was suspended in 0.4 mol/L HCl in an EtOH/H2O mixture
(1:1.25) and shaken for the selected time. The resin was removed by filtration, washed and the
filtrate taken to dryness with a rotary evaporator. The residue was treated with H2O and adjusted
to pH=5−6 with 0.1 mol/L NaOH. This solution was diluted to 10 mL and analyzed by HPLC
against standard solutions.

Solvent compatibility of resins 1 or 4
Resin 1 or 4 was ground into a fine powder with a mortar and pestle. A NMR tube was
filled with this powder to a height of about 10 mm, then 1 mL of a selected solvent was added to
the NMR tube. After stirring to ensure wetting of the powder, the suspension was allowed to
settle for 24 h and the height of the resin column in the tube was re-measured. Solvent
compatibility was calculated as [(volume of wet resin [minus] volume of dry resin)/volume of
dry resin].
Alternatively, about 100 mg of resin 1 or 4 in a 4 dram vial was soaked in an excess of
the selected solvent for 24 h. The suspension was transferred to a tared sintered glass funnel and
vacuum filtered until the bulk of the solvent had been removed. The funnel and contents were
then weighed. The decrease in weight was followed for a period of 2 h by which time the weight
remained constant near the original weight for most solvents except DMSO. Solvent
compatibility was calculated as [(weight of wet resin [minus] volume of dry resin)/volume of dry
resin].

General procedure for the iodinolysis of resins
To a suspension of resin (~20 mg) in ~2 mL acetonitrile (CH3CN), ~1 mL of I2/CH3CN
(0.1 mol/L) was added. After shaking at RT for 2 h, an aqueous solution of sodium thiosulfate
(0.2 mol/L) was added until a colorless solution was obtained. Upon dilution to 25 mL with
MeOH, a portion of this suspension was filtered through a Whatman 0.45 µm nylon syringe
filter. These solutions were analyzed by HPLC against a standard solution of the appropriate
authentic iodo-compound for both retention time and area (see Supplementary data for HPLC
conditions and for synthesis of standards where appropriate).
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Preparation of (4S, 5S)-2-(3- and 4-Bromophenyl)-3, 4-dimethyl-5-phenyl-1, 3-oxazolidine
(9a and 9b)
Into a one-necked 250 mL round-bottomed flask, equipped with a Dean−Stark trap and a
condenser, was placed 3-bromobenzaldehyde (7a, 8.78 g, 47.5 mmol) and (S,S)-(+)pseudoephedrine (8, 7.83 g, 47.4 mmol), and benzene (180 mL). After 18 h reflux, benzene was
removed under reduced pressure, to give a yellow oil which solidified upon standing. A white
solid (m.p. 73−75°C) was obtained after recrystallization from hexanes (9a), 14.78 g (94%). 1H
NMR spectrum (CDCl3,) δ: 7.75 (s, 1H), 7.51−7.26 (m, 8H), 4.93 (s, 1H), 4.76 (d, 1H, 3JH-H =
7.2 Hz), 2.56 (m, 1H), 2.23 (s, 3H), 1.23 (d, 3H, 3JH-H = 5.6 Hz). 13C NMR spectrum (CDCl3,) δ:
141.96, 139.91, 132.08, 130.95, 129.86, 128.37, 128.00, 126.76, 126.61, 122.50, 98.60, 86.60,
68.62, 35.12, 14.23. IR spectrum (CH2Cl2, cm-1): 2972 and 2792 (C−H), 1575 and 1460 (C=C),
1043 (C−O). HRMS, m/z: calcd. for C16H18NO79Br 332.0650, found 332.0644.
Analogously, 4-bromobenzaldehyde (7b, 500 mg, 2.7 mmol), (S,S)-(+)-pseudoephedrine
(8, 450 mg, 2.7 mmol) and benzene (40 mL) were refluxed for 18 h. Solvent evaporation yielded
a clear, colorless, viscous oil (9b), 883 mg (98%). 1H NMR spectrum (CDCl3) δ: 7.42 (d, 2H,
3

JH-H = 8.4 Hz), 7.35−7.20 (m, 7H), 4.82 (s, 1H), 4.65 (d, 1H, 3JH-H = 8.4 Hz), 2.45 (m, 1H), 2.09

(s, 3H), 1.12 (d, 3H, 3JH-H = 6.0 Hz). 13C NMR spectrum (CDCl3) δ: 139.97, 138.53, 131.38,
129.68, 128.33, 127.94, 126.56, 122.91, 98.69, 86.50, 68.59, 35.00, 14.19. IR spectrum (CH2Cl2,
cm-1): 2974 and 2793 (C-H), 1594, 1489 and 1456 (C=C), 1043 (C−O). HRMS, m/z: calcd. for
C16H18NO79Br 332.0650, found 332.0647.
Poly-(4S, 5S)-2-(3- and 4-{dibutyl[2-(3-and 4-vinylphenyl)ethyl]stannyl}phenyl)-3, 4dimethyl-5-phenyl-1, 3-oxazolidine)-co-divinylbenzene (Resin 10a and 10b)
To (4S, 5S)-2-(3-bromophenyl)-3,4-dimethyl-5-phenyl-1,3-oxazolidine (9a, 2.90 g, 8.7
mmol) in a three-necked flask equipped with a T-bore stopcock, a rubber septum and a powder
addition side arm containing resin 1 (4.01 g, 5.9 mmol Sn−Cl) was added dry THF (30 mL)
under Ar. To this solution was added n-BuLi (3.0 mL, 7.5 mmol, 2.5 mol/L) at -78°C. After 2 h
at -78°C, resin 1 was tipped into the THF solution, the suspension was allowed to stir for about
18 h as it warmed to RT. MeOH (3 mL) was added and the suspension was filtered and washed
with MeOH, H2O, MeOH/H2O/acetone, MeOH/acetone, and MeOH several times to yield 4.3 g
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of resin 10a after drying. MAS 119Sn NMR spectrum (toluene): -41.8 ppm. DRIFT-IR spectrum
(solid, cm-1): 1044 (C−O).
Similarly, (4S, 5S)-2-(4-bromophenyl)-3,4-dimethyl-5-phenyl-1,3-oxazolidine (9b, 1.02
g, 3.1 mmol) in dry THF (35 mL) was reacted with n-BuLi (2.5 mol/L, 1.2 mL, 3.0 mmol) and
resin 1 (1.05 g, ~1.6 mmol Sn−Cl) to yield 1.24 g of resin 10b. MAS 119Sn NMR spectrum
(toluene): -42.1 ppm. DRIFT-IR spectrum (solid, cm-1): 1048 (C−O).

Poly-(3- and 4-{dibutyl[2-(3-and-4-vinylphenyl)ethyl]stannyl}benzaldehyde)-codivinylbenzene (Resins 11a and 11b)
Resin 10a (3.98 g) was treated with a mixture of AcOH (25 mL), MeOH (25 mL), and
H2O (9 mL) with gentle shaking at RT for 27 h. The solid was recovered by filtration and was
washed successively with MeOH, H2O, MeOH/H2O/acetone, MeOH/acetone, and MeOH to
yield 3.65 g of resin 11a. MAS 119Sn NMR spectrum (toluene): -39.2 ppm. DRIFT-IR spectrum
(solid, cm-1): 2716 (aldehyde C−H stretch), 1699 (aldehyde C=O), 1645 (aldehyde C=O).
Iodinolysis: 1.05 mmol of 10a per gram of resin 11a.
Resin 10b (1.22 g) was treated with a mixture of MeOH (5 mL), H2O (1.5 mL), and
AcOH (5 mL) with shaking at RT for 17 h. The solid was filtered and washed to yield 1.00 g of
resin 11b. MAS 119Sn NMR spectrum (toluene): -39.8 ppm. DRIFT-IR spectrum (solid, cm-1):
2715 (CHO); 1707 (C=O). Iodinolysis: 0.78 mmol of 10b per gram of resin 11b.

Poly-(3- and 4-{dibutyl[2-(3-and-4-vinylphenyl)ethyl]stannyl}benzoic acid)-codivinylbenzene (Resins 12a and 12b)
Resin 11a (103 mg, ~0.087 mmol of aldehyde) was added to a vial and swollen with
reagent grade MeOH (5 mL). To the mixture was added mCPBA (~93%, 102 mg, 0.20 mmol).
After shaking for 24 h at RT, the solid was filtered and washed successively with 1 mol/L
NaOH, acetone, 1.7 mol/L AcOH/EtOH, H2O, MeOH/H2O/acetone, and MeOH to afford 93 mg
of resin 12a. MAS 119Sn NMR spectrum (toluene): -39.7 ppm. DRIFT-IR spectrum (solid, cm-1):
3700-2500 (O−H), 1718 (C=O), 1689 (C=O). Iodinolysis: 0.93 mmol of 14a and 0.01 mmol of
13a per gram of resin 12a.
As per resin 11a, resin 11b (210 mg, ~0.15 mmol) was treated with mCPBA (~90%, 298
mg, 0.6 mmol) in MeOH (5 mL) to yield 188 mg of resin 12b. MAS 119Sn NMR spectrum
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(CHCl3): -40.9 ppm. DRIFT-IR spectrum (solid, cm-1): 3600−2500 (O−H, broad), 1725 and 1691
(C=O). Iodinolysis: 0.66 mmol of 14b and 0.03 mmol of 13b per gram of resin 12b.

Typical procedure for preparation of resin-supported stannyl-bound dialkyldiamines
(Resins 19a and 19b) from Resins 12a and 12b.
Poly-(4-{dibutyl[2-(3-and 4-vinylphenyl)ethyl]stannyl}-N,N-diethylethylene
diaminobenzamidyl)-co-divinylbenzene (19b-2)
Into a 50 mL round-bottom flask were placed N,N-diethylethylenediamine (28 mg, 0.24
mmol), collidine (27 mg, 0.22 mmol), DCC (61 mg, 0.30 mmol), 1-HOBT (32 mg, 0.21 mmol),
resin 12b (150 mg, ~0.10 mmol), and DCM (5 mL). After stirring under an atmosphere of argon
for 7 days at RT, the solid was filtered and washed with MeOH/acetone, DCM, and MeOH
solutions successively (3 x 15 mL), to yield 150 mg of resin 19b-2. MAS 119Sn NMR spectrum
(CHCl3): -41.2 ppm. DRIFT-IR spectrum (solid, cm-1): 1653 (C=O), 3343 (N−H). Iodinolysis:
0.40 mmol N,N-(2-diethylaminoethyl)-4-iodobenzamide 20b-2, 0.10 mmol of 14b and 0.05
mmol of 13b per gram of resin.
The same procedure was utilized for the formation of the library of resin-bound stannyl
benzamides (19a/b) by substituting different diamines for N,N-diethylethylenediamine. MAS
119

Sn NMR spectra (CHCl3) showed one peak in the range -39.8 to -41.2 ppm. DRIFT-IR spectra

(solid, cm-1) showed C=O absorptions in the range 1637 to 1653 and N−H around 3343.
Iodinolysis results are presented in Table 2.

General procedure for the preparation of resin-supported 3- and 4-stannyl N-succinimidyl
benzoates (16a and 16b) from resin 12a and 12b.
Resin-supported benzoic acid (50 mg 12a or 12b) was swollen with DCM for 10 min and
to this was added EDC (59 mg, 0.31 mmol), NHS (35 mg, 0.30 mmol), collidine (52 mg, 0.43
mmol), and DCM (4 mL). The NHS solution was then added to the resin suspension followed by
stirring at RT for 24 h. The suspension was filtered and the resin was washed with DCM and
acetone several times to yield the corresponding resin-bound active ester 16a or 16b.
16a: MAS 119Sn NMR spectrum (toluene): -38.5 ppm (Sn−aryl). DRIFT-IR (solid, cm-1): 1772
(C=O (asymmetric)), 1746 (C=O (symmetric)), 1071 (C−N). Iodinolysis: 0.69 mmol of 17a and
0.13 mmol of 14a per gram of resin.
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16b: MAS 119Sn NMR spectrum (toluene): -39.4 ppm (Sn−aryl). DRIFT-IR (solid, cm-1): 1773
(C=O (asymmetric)), 1743 (C=O (symmetric)). Iodinolysis: 0.53 mmol of 17b and 0.06 mmol of
14b per gram of resin.

General procedure for the preparation of resin-supported 3- and 4-stannyl benzamides
(19a and 19b) from resin 16a and 16b.
Resin-supported active ester (200 mg, 16a or 16b) was swollen with DCM (5 mL) for 10
min. To resin was added diamine and the reaction was allowed to stir for 24 h at RT. The solid
was filtered and washed with MeOH, acetone/H2O, MeOH/H2O/acetone and MeOH to yield a
library of resin-bound stannyl benzamides (19a/b) using three N,N-dialkylpropyldiamines for
resin 16a and one N,N-dialkylethyldiamine for resin 16b, as shown in Table 3.
MAS 119Sn NMR spectra (CHCl3) showed one peak in the range -39.8 to -40.2 ppm.
DRIFT-IR spectra (solid, cm-1) showed C=O absorptions in the range 1637 to 1640 and amide
N−H stretch, 3285-3307; 1537-1540 (amide N−H deformation).
Iodinolysis results presented in Table 3 are a combination of two separate analyses since
N-succinimidyl-3-iodobenzoate does not survive the pH 5 conditions.

Typical procedure for preparation of resin-supported 4-stannyl-benzamides by direct
addition from Resin 1:
Poly-(4-{dibutyl[2-(3-and 4-vinylphenyl)ethyl]stannyl}-N,N-diethylpropylene
diaminobenzamidyl)-co-divinylbenzene (19b-9)
A three-necked round-bottomed flask, equipped with a T-bore stopcock, a rubber septum,
stir bar, and a powder addition side arm containing of resin 1 (175 mg, 1.67 mmol/g, 0.3 mmol)
was evacuated and N2 introduced. Freshly distilled THF (40 mL) was added via syringe. The
flask and its contents were cooled to -78 °C, evacuated and N2 introduced. Then t-BuLi (770 µL,
1.2 mmol) was added dropwise to afford a 0.03 mol/L solution. N-(3-(Diethylamino)propyl)-4bromobenzamide (184 mg, 0.59 mmol) in dry THF (1 mL) was added dropwise by syringe with
vigorous stirring. After 2 h at -78 °C, the resin was tipped into the solution and left to stir as the
suspension warmed slowly to RT. After MeOH addition (3 mL), the suspension was filtered and
sequentially washed with MeOH/acetone, MeOH/H2O, MeOH/acetone/H2O, and MeOH several
times to afford ~180 mg of resin 19b-9 after drying. 119Sn MAS NMR spectrum (toluene): 82.0
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ppm (Sn−O) and -40.8 ppm (Sn−aryl). DRIFT-IR spectrum (solid, cm-1): 1637 (amide C=O)
3319 and 1538 (amide N−H). Iodinolysis: 0.37 mmol N-(3-(diethylamino)propyl)-4iodobenzamide 20b-9 per gram of resin.
Radiolabeling of [131I]-N-(2-morpholin-4-ylethyl)-4-iodobenzamide
Radioiodination was carried out by adding 100 µL of 0.1 mol/L H3PO4, 70 µL of n.c.a.
Na131I (150 MBq (4.05 mCi) in 0.1% aq. NaOH) and 25 µL of peracetic acid solution (1 mL of
glacial AcOH and 1.7 mL of 30% aq. H2O2) into a 2 mL vial containing a methanolic suspension
of resin 19b-7 (3.2 mg in 100 µL). After 15 min at RT with stirring, 100 µL of 0.2 mol/L
Na2S2O3 was added to quench any excess iodine. The insoluble material was then passed through
a Whatman 0.45 µm nylon syringe filter. The filtrate containing the desired product was
analyzed by radio-HPLC (C18, 4.6 x 250 mm) with CH3CN/Na2HPO4 buffer (5 mmol/L, pH 7) as
the mobile phase. Radiochemical yield (RCY) was defined as: [isolated radioactive ligand,
MBq]/[total radioactivity added, MBq].
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Available with the article: HPLC conditions, experimental procedures for iodobenzamide
standards and SPE benzamide purification, resin SEM, MAS 119Sn NMR and DRIFT-IR spectra
for resins, and HPLC chromatograms of SPE benzamide purification. Supplementary data are
available with the article through the journal Web site at
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Figures and Tables

Fig. 1. Schematic of cross-linked polystyrene-based chlorostannane resin 1.
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Fig. 2. Routes of preparation and release of benzene derivatives from stannyl resins.
R=Intermediate functionality, W=Target functionality, *A=Radionuclide, HX=Acid and E+=Electrophile
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Fig. 3. Hydrolysis and regeneration of Resin 1
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Table 1. Incorporation of solvents into resins 1 and 2 determined by weight and volume
increase.
EtOH

H2O

EtOH/ H2Oa DMSO

THF

CH3CN

C6H6

C7H8

Resin 1

1.5b/1.7c

0/0

0.44b

2.6/3.2

1.6/2.0

1.0/1.5

1.5/2.6

0.9/1.2

Resin 4

1.4/3.0

0.36/0.4

1.9b

2.3/2.2

1.2/2.8

0.3/1.3

0.5/1.5

0

a

EtOH/H2O1.25:1
Weight ratios defined as: [(wt of resin + solvent) – wt of resin]/wt of resin
c
Volume ratio: [(volume of resin + solvent) – volume of resin]/volume of resin
b
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Fig. 4. Iodo- and protodestannylation of Resin 4. A=halide, SO42-, ClO4-, NO3-
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Fig. 5. Preparation of resin-supported benzoic acids (12a and 12b) from the corresponding bromobenzaldehydes
(#0.05 and 0.01 mmol/g of 13a and 13b detected, respectively). Reagents and conditions: (A) Reflux, benzene; (B)
(i) n-BuLi, -78°C, THF (ii) Resin 1; (C) AcOH/H2O/MeOH; (D) 3-Chloroperbenzoic acid; (E) I2/CH3CN.
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Fig. 6. Indirect approaches evaluated for synthesis of resin-supported benzamides.
-

Reagents: (A) Amines, DCC; (B) NHS, EDC; (C) Amines/amino acids/proteins; (D)*I , oxidant
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Fig. 7. Preparation of resin-bound benzamides 19a/b (both routes). Iodinolysis (condition B) results in a mixture of
iodobenzamides, iodobenzoic acids and iodobenzaldehydes. See Table 2 for examples of mixture ratios.
Reagents and conditions: (A) DCC, HOBT, DCM, diamine, 7 d; (B) I2, CH3CN; (C) EDC, NHS, 24 h; (D) diamine,
24 h.
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Table 2. Library of resin-bound 4-stannyl dialkylaminoethyl and propyl benzamides (19b-1 to
19b-12) prepared by amine/DCC/1-HOBT coupling with the resin-bound acid 12b.
Iodinolysis (mmol/g)a

Resin
19b

nb

R

4-iodobenzamide

4-iodo-benzoic
acid

4-iodobenzaldehyde

1

2

CH3

0.36

0.23

0.06

2

2

CH2CH3

0.40

0.10

0.05

3

2

CH(CH3)2

0.35

0.20

0.06

4

2

CH2CH2CH2CH3

0.39

0.14

0.06

5

2

(CH2)4

0.32

0.29

0.05

6

2

(CH2)5

0.41

0.17

0.05

7

2

(CH2)2(CH2)2O

0.54

0.11

0.06

8

3

CH3

0.41

0.25

0.06

9

3

CH2CH3

0.29

0.27

0.10

10

3

CH2CH2CH2CH3

0.17

0.33

0.03

11

3

(CH2)4

0.24

0.32

0.05

12

3

(CH2)2(CH2)2O

0.40

0.18

0.04

a

HPLC conditions: µBondapak C18 column (4.6 x 250 mm); 60:40 MeOH/NaH2PO4 buffer [pH
5]; 1 mL/min.
b
n is the number of CH2 groups in the diamine moiety of the benzamides (see Fig. 7).
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Table 3. Iodinolysis results of resin-bound dialkyalaminoalkyl benzamides 19a and 19b
prepared by coupling through N-succinimidyl ester bound resins 16a and 16b, respectively.
Iodinolysis (mmol/g)

Resin
19

n

R

iodobenzamideb

N-succinimidyliodobenzoatec

iodobenzoic
acidb

a-1

3

CH2CH3

0.75

0.02

0.13

a-2

3

CH2CH2CH2CH3

0.59

0.02

0.15

a-3

3

(CH2)4

0.64

0.01

0.17

b-2

2

CH2CH3

0.43

n.d.d

0.09

a

a

n is the number of CH2 groups in the diamine moiety of the benzamides (see Fig. 7).
HPLC conditions: µBondapak C18 column (4.6 x 250 mm); 60:40 MeOH/NaH2PO4 buffer [pH
5]; 1 mL/min.
c
HPLC conditions: µBondapak C18 column (4.6 x 250 mm); 50:50 CH3CN/Na2HPO4 buffer [pH
7]; 1 mL/min.
d
n.d. = not determined.
b
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Fig. 8. Preparation of resin-bound benzamide 19b-11 by direct addition of dilithiated benzamide intermediate to
resin 1.
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Fig. 9. RadioHPLC chromatograms following radioiodinlysis of resin-bound benzamide 19b-7 treated with
Na131I/H2O2/AcOH for 15 min at RT (A) after filtration and (B) after SPE purification.
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